The small-molecule TNF-α modulator, UTL-5g, reduces side effects induced by cisplatin and enhances the therapeutic effect of cisplatin in vivo

Journal of Experimental Therapeutics and Oncology

Volumn 9, Issue 2, 2011, Pages 129-137

  Shaw, JiaJiu ^a   Chen, Ben ^b   Huang, Wen Hsin ^c   Lee, An Rong ^c   Media, Joseph ^d   Valeriote, Frederick A ^d  

^a 21St Century Therapeutics Inc   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Chemoprotective agent; Cisplatin; Side effects; Therapeutic effect; TNF

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIFOSTINE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; CREATININE; LEFLUNOMIDE; NITROGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UREA; UTL 5G;

ACUTE TOXICITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; IN VIVO STUDY; LD 50; LEUKOCYTE COUNT; LIVER TOXICITY; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCID MOUSE; THERAPY EFFECT; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL;

ACUTE TOXICITY TESTS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD UREA NITROGEN; CELL LINE, TUMOR; CISPLATIN; COLONIC NEOPLASMS; DRUG-INDUCED LIVER INJURY; FEMALE; HEMATOLOGIC DISEASES; HUMANS; ISOXAZOLES; KIDNEY DISEASES; LETHAL DOSE 50; MALE; MICE; MICE, INBRED ICR; MICE, SCID; PLATELET COUNT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959269452     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Madias NE, Harrington JT. Platinum nephrotoxicity. Am J Med 65:307-314, 1978. (Pubitemid 9003377)
2. Cavalli F, Tschopp L, Sonntag RW, Zimmermann A. A case of liver toxicity following cis-dichlorodiammineplatinum(II) treatment. Cancer Treat Rep 62:2125-2126, 1978. (Pubitemid 9145243)
3. Cersosimo RJ. Hepatotoxicity associated with cisplatin chemotherapy. Ann Pharmacother 27:438-441, 1993. (Pubitemid 23123892)
4. Pollera CF, Ameglio F, Nardi M, Vitelli G, Marolla P. Cisplatin-induced hepatic toxicity. J Clin Oncol 5:318-319, 1987.
5. Gill I, Muggia FM, Terheggen PM, Michael C, Parker RJ, Kortes V, Grunberg S, Christian MC, Reed E, den Engelse L. Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): tolerance and relation to leukocyte and buccal cell platinum-DNA adducts. Ann Oncol 2:115-121, 1991.
6. Kelland LR, Sharp SY, O'Neill CF, Raynaud FI, Beale PJ, Judson IR. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. J Inorg Biochem 77:111-115, 1999. (Pubitemid 30089090)
7. Psotova J, Chlopcikova S, Miketova P, Hrbac J, Simanek V. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part III. Apigenin, baicalelin, kaempherol, luteolin and quercetin. Phytother Res 18:516-521, 2004.
8. Subbiah U, Raghunathan M. Chemoprotective action of resveratrol and genistein from apoptosis induced in human peripheral blood lymphocytes. J Biomol Struct Dyn 25:425-434, 2008.
9. Culy CR, Spencer CM. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 61:641-684, 2001. (Pubitemid 32454529)
10. Korst AE, Gall HE, Vermorken JB, van der Vijgh WJ. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient. Cancer Chemother Pharmacol 39:162-166, 1996. (Pubitemid 26400676)
11. Markman M. Amifostine in reducing cisplatin toxicity. Semin Oncol 25:522-524, 1998. (Pubitemid 28478058)
12. Phillips KA, Tannock IF. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 16:3179-3190, 1998. (Pubitemid 28417441)
13. Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamulu P, Reddy D, Petluru P, Zhao M, Murali D, Saxe JD, Yao S, Martinez N, Zukowski A, Rustum YM. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Semin Oncol 25:584-599, 1998. (Pubitemid 28478065)
14. Mabro M, Faivre S, Raymond E. A risk-benefit assessment of amifostine in cytoprotection. Drug Saf 21:367-387, 1999.
15. Demiral AN, Yerebakan O, Simsir V, Alpsoy E. Amifostine-induced toxic epidermal necrolysis during radiotherapy: a case report. Jpn J Clin Oncol 32:477-479, 2002. (Pubitemid 43102770)
16. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110:835-842, 2002.
17. Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 285:F610-618, 2003.
18. Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 289:F166-174, 2005.
19. Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8:368-379, 1986. (Pubitemid 17235084)
20. Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Kishihara K, Hirakata H, Iida M. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 63:72-82, 2003. (Pubitemid 35463908)
21. Zhang B, Ramesh G, Norbury CC, Reeves WB. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int 72:37-44, 2007. (Pubitemid 47014442)
22. Ramesh G, Kimball SR, Jefferson LS, Reeves WB. Endotoxin and cisplatin synergistically stimulate TNF-alpha production by renal epithelial cells. Am J Physiol Renal Physiol 292: F812-819, 2007.
23. Ma Q, Kinneer K. Chemoprotection by phenolic antioxidants. Inhibition of tumor necrosis factor alpha induction in macrophages. J Biol Chem 277:2477-2484, 2002. (Pubitemid 34953270)
24. Shaw J, Liu C, Martin R, Chen B, Holtz R, Huang WH, Lee AR. Inhibition of tumour necrosis factor-alpha secretion from EpiDermTM tissues by a novel small molecule, UTL-5d. Br J Dermatol 157:575-579, 2007. (Pubitemid 47256120)
25. Qian J, Shaw J, Lawrence TS, Zhang M. TNF-alpha modulator as radioprotective agent for liver. AACR Meeting Abstracts 2005:468, 2005.
26. NIH. The Revised Up-and-Down Procedure: A Test Method for Determining the Acute Oral Toxicity of Chemicals. NIH Publication No 02-4501 Volumes 1 and 2, 2001.
27. Reed E. Cisplatin and Its Analogs. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 8 ed. Philadelphia: Lippincott Williams & Wilkins 419-426. 2008.
28. Nogami W, Yoshida H, Koizumi K, Yamada H, Abe K, Arimura A, Yamane N, Takahashi K, Yamane A, Oda A, Tanaka Y, Takemoto H, Ohnishi Y, Ikeda Y, Miyakawa Y. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis. Haematologica 93:1495-1504, 2008.
29. Nurden AT, Viallard JF, Nurden P. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet 373:1562-1569, 2009.
30. Ramesh G, Reeves WB. Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney Int 65:490-499, 2004.
31. Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35:1270-1273, 1996. (Pubitemid 26050790)
32. Huang WH, Yang CL, Lee AR, Chiu HF. Leflunomide analogues as potential antiinflammatory agents. Chem Pharm Bull (Tokyo) 51:313-314, 2003.
33. Gonzalez-Alvaro I, Ortiz AM, Dominguez-Jimenez C, Aragon- Bodi A, Diaz Sanchez B, Sanchez-Madrid F. Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway. Ann Rheum Dis 68:1644-1650, 2009.
34. Shaw J, Chen BD, Wooley P, Huang WH, Lee AR, Zeng D. Antiinflammatory and Anti-arthritic Effects of a Novel Leflunomide Analogue, UTL-5b (GBL-5b) Am J Biomed Sci:(in the press), 2010.
35. Davison C, Zimmerman EF, Smith PK. On the metabolism and toxicity of methyl salicylate. J Pharmacol Exp Ther 132:207-211, 1961.
36. Eriksson M. Salicylate-induced foetal damage during late pregnancy in mice. The modifying effect of repeated administration and dosage. Acta Paediatr Scand 59:517-522, 1970.